Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 30, 2018

Primary Completion Date

December 1, 2022

Study Completion Date

January 20, 2023

Conditions
Adenocarcinoma of the PancreasPancreatic CancerAdvanced CancerDigestive System NeoplasmsPancreatic NeoplasmsEndocrine Gland NeoplasmsDigestive System DiseasesEndocrine System DiseasesPancreatic Diseases
Interventions
DIETARY_SUPPLEMENT

Ocoxin-Viusid®

"An oral solution of Ocoxin-Viusid® (30 ml vials) will be used at a rate of 60 ml daily (1 vial every 12 hours), preferably administered after breakfast and lunch. It will be prescribed for a period of 2 weeks before starting the QT.~The treatment with Ocoxin-Viusid® will continue in the possible periods of time of suspension of the chemotherapy treatment due to toxicities attributable to the oncospecific treatment.~The treatment will be administered continuously from the inclusion of the patient in the study, up to one year."

Trial Locations (1)

10300

"Hermanos Ameijeiras Surgical Clinical Hospital", La Habana

All Listed Sponsors
lead

Catalysis SL

INDUSTRY

NCT03717298 - Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma | Biotech Hunter | Biotech Hunter